Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Revelation 2:3
"You have persevered and have endured hardships for my name and have not grown weary."
I appreciate the advice. Question: What if, for example, I write a June 2022 $50 covered call and auph is aquired for $40 in January 2022 ?
Good morning to all longs. Any exit strategy suggestions? Might Monday morning short covering be a good time to sell some shares? Or wait for more info? Anyone putting in a good-til-cancelled limit sell order?
I've been very long auph for 4 1/2 years, holding my position through thick and thin. I sure don't want to screw it up now. Thanks for any suggestions.
Hospital gowns are like medical insurance.
You think you're covered but you're not.
Merriam-Webster's definition of 'aquire':
- "to come into possession or control of often by unspecified means"
If you come into possession of stock then you have aquired it, regardless of how you came to possess the stock.
Merck looks at M&A deals
Merck CEO: "“We are open to any opportunity to add a meaningful asset.”
link to article
40% of Lupus Nephritis patients are black.
Apparently, black lives DON'T matter to ICER, but do matter to CIGNA. Let's see how much BLM to the other health insurance companies.
Next earnings call May 12th-17th (says Yahoo)
Transcription of the script number Q&A:
Question:
“Do you have any guidance on script numbers for Lupkynis?”
Response:
“We’ve not given script numbers yet. We’ll only do that in one of our earnings calls that’s upcoming, but perhaps I can say this. That the analysts projected that we’ll sell somewhere between 74 and 75 million in the first year of sales, and we’re comfortable with that guidance and obtaining those goals.”
ICER doesn't appreciate the 2037 patent extension.
Who profits by denying patient access to drugs?
Insurance companies. Talk about the fox guarding the hen house!
Here is an interesting site: link
"...make no mistake about who ICER is serving."
"In the U.S., the 800-pound gorilla of cost-effectiveness analyses is the Institute for Clinical and Economic Review (ICER), which calls itself “an independent and non-partisan research organization.” But with a governing board stacked with insurance industry executives, patients and drug innovators should make no mistake about who ICER is serving."
link to article
The percent increases in my post were calculated after the recent price drop. The point I was making is that, despite the recent sp drop, AUPH has handsomely rewarded shareholders who bought their stock two or five years ago.
To look on the bright side: AUPH is up 140% in the last two years and 640% in the last 5 years.
"A Better Value Today At $17 Than It Was A Month Ago At $14"
stockadvisor
MarketEdge just upgraded AUPH from NEUTRAL to LONG:
"The technical condition of the stock is supportive of higher prices. The stock remains in demand and support levels should hold as the trend continues higher. The stock has outperformed the market over the last 50 trading days when compared to the S&P 500. The MACD-LT is confirming that the intermediate-term trend is bullish. AUPH's chart formation indicates a strong rising trend. Upside momentum, as measured by the 9-day RSI indicator is positive but is beginning to slow. Over the last 50 trading sessions, there has been more volume on up days than on down days, indicating that AUPH is under accumulation, which is a bullish condition. The stock is trading above a rising 50-day moving average. This validates the strong technical condition for AUPH. The stock is above its 200-day moving average which is pointed up indicating that the intermediate term trend is bullish."
Is there no end to the drama? I'm a newbie to biopharm investing. Silly me, I thought the phase 3 results were the goal line, but then the sp dropped from 21 to 12. I know the FDA decsion is absolutely wonderful, but I fear the drama is not over. I'm going to enroll my wife in CPR training.
AUPH improved my financial situation immensely, and that is due almost entirely to the regular posters on this iHUB message board. No way I would have invested so heavily in AUPH, and held my all-eggs-in-one-basket position for the last almost four years, without your positivity. I knew all along that I should not have had such a large percentage of my portfolio in one stock, but I took the gamble anyway. I will never do it again. The price fluctuations were extremely painiful to live thru, and the recent FDA approval process was scary as hell, but here we are, finally. So thank you all, a lot. Now what? When to divest?
See post #11850
I had more fun waiting for my prostate biopsy results.
Why in the world would FDA not approve VOC?
Stay strong.
If the sp drop is due to the non-US marketing agreement, then the drop is unwarranted. Aurinia gets $100 million upfront and then will get 10%-20% of future overseas net sales. "Net sales' is very different from "net profit", which seems to be the misunderstanding. Aurinia gets a good return with no additional costs incurred. The US market is the big payoff.
Worth reposting:
“The Efficacy and Safety of Belimumab in Patients with Active Lupus Nephritis (BLISS-LN) study, involving 448 patients, met its primary endpoint demonstrating that a statistically significant greater number of patients achieved Primary Efficacy Renal Response (PERR) over two years when treated with belimumab plus standard therapy compared to placebo plus standard therapy in adults with active LN (43% vs 32%, odds ratio (95% CI) 1.55 (1.04, 2.32), p=0.0311).”
Oh yeah Benlysta is considerably crappier. 11% delta vs 18% for VOC and a p value of .0311 for VOC <.001. Yeah not worried at all
I wouldn't jump out a window just yet. Short interest went from 3.9% to 4.7%. Still relatively low.
Pease don't alienate these guys. I'm up seven figures in AUPH because of them. I'll name my next kid MEAT if it keeps them posting.
Billionaire Jim Simons Pulls the Trigger
link to article
Better Buy: Amarin vs. Aurinia Pharmaceuticals
link to article
I see what Hotrodder means.
Here is a better link to that article: better link
Positive AUPH article:
Link to article
Something's coming, something good,
If I can wait!
Something's coming,
I don't know what it is,
But it is
Gonna be great!
...and another: article
Is Aurinia Pharmaceuticals Stock a Buy?
link to article
Thank you all for posting your continued confidence in AUPH. I was starting to worry when no one was posting. I still have 50,000 shares bought for an average sp of $4.88 in March 2017. But I would have sold long ago were it not for the intelligent comments of the posters on this board. That is an absolute fact. Question for you guys: If Aurinia received a BO offer that they declined, must they disclose it?
OMG, a three day low.
I am replying to my post from over two years ago, and I have been long AUPH for even longer. I cannot give enough thanks to the longs who regularly posted on this board over the past three years. I would have sold long ago were it not for your knowledge and belief in AUPH. Lots of new names showing up today on this board, but everyone knows who the regular posters have been. Thank you soooooo much guys. What a wild ride. I watched the sp go up and down so many times, always tempted to try timing the highs and lows, but because of you guys I never sold any of my 54,000 shares. What a day. But, now what should I do
A stock goes up 15% in one day and you draw a chart and broadcast to the world your spectacular conclusion that a bullish move occurred? Anyone can put a bumper sticker on after the election.
If DES were the only indication, what do you think the SP would be?